Humulin Regular

Quick links to important sections

Humulin Regular

Method of action: Drugs Used In Diabets

Treatment option: Diabetes Mellitus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Humulin Regular

What is Humulin Regular?

Humulin Regular is a short-acting insulin, often referred to as soluble or neutral insulin. It is a laboratory-produced version of the hormone insulin, which is naturally created by the pancreas. This medication is identical in structure to the insulin produced by the human body.

Mechanism of Action

Humulin Regular works by facilitating the transport of glucose from the bloodstream into the body's cells, where it is used for energy. It also helps the liver, muscle, and fat tissue store glucose for later use. By regulating these processes, it helps maintain stable blood sugar levels in individuals whose bodies do not produce sufficient insulin or cannot use insulin effectively.

Characteristics and Duration

As a short-acting insulin, Humulin Regular begins to work relatively quickly after administration, typically reaching its peak effect within a few hours. Its effects last for a moderate duration, providing a window of activity that helps manage blood glucose levels, particularly following meals.

Composition

Humulin Regular is a clear, sterile solution. It is produced using recombinant DNA technology, a process that involves using specific organisms to create the insulin protein. Because it is chemically identical to human insulin, it is classified as a human insulin product, distinguishing it from older insulin formulations derived from animal sources.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Humulin Regular ?

The safety profile of human insulin (Humulin Regular) is formally documented in government regulatory sources, classifying potential adverse reactions by frequency and physiological system. This information is designed to describe the known risks without providing clinical advice or usage instructions.

Frequency-Classified Adverse Reactions

The most frequent adverse reaction is hypoglycemia (low blood sugar), which is classified as Very Common in regulatory documents [FDA DailyMed]. This is an expected consequence of the medicine's primary action. Local injection site reactions (such as redness, swelling, or itching) are classified as Common. Changes in the appearance of the skin tissue at the injection site, known as lipodystrophy, along with systemic (generalized) allergic reactions, are listed as Uncommon.

Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights Severe Hypoglycemia as a serious adverse reaction, noting its potential to lead to convulsions or loss of consciousness. Anaphylaxis, a severe form of systemic hypersensitivity, is also documented as a rare but serious event [EMA SmPC].

The safety documentation notes that the risk of hypoglycemia may be increased during periods of dose adjustment or in individuals with pre-existing renal or hepatic impairment. Furthermore, the medicine is contraindicated in patients who are actively experiencing an episode of hypoglycemia. High-level warnings also address the potential for Hypokalemia (low potassium) and the risk of worsened edema when used alongside thiazolidinediones.

Overdose and Emergency Response

An overdose of Human Insulin (Humulin Regular) is formally documented as resulting in hypoglycemia, which is the exaggerated lowering of blood glucose levels. This condition may initially present with adrenergic symptoms such as sweating, tremors, and palpitations, alongside neuroglycopenic signs like headache, listlessness, and confusion.

Uncorrected severe hypoglycemia poses a risk of life-threatening complications affecting the Central Nervous System. Officially documented severe outcomes include seizures, unconsciousness or coma, and the risk of temporary or permanent brain function impairment. Regulatory information also notes the metabolic risk of hypokalemia, which is considered potentially life-threatening.

Immediate medical attention is required for any severe episode, particularly those involving loss of consciousness, seizure, or neurological impairment. Regulatory authorities mandate contacting emergency services, such as a Poison Help line, for assistance. Management procedures include the administration of counteragents like Glucagon or Concentrated Intravenous Glucose Solution. Due to the risk of hypoglycemia recurrence, close monitoring of blood glucose and potassium levels is required during treatment and sustained post-recovery observation. Patients with renal or hepatic impairment have an increased risk profile for these effects.

Therapeutic Uses of Humulin Regular

What Humulin Regular Treats: Main Uses and Benefits

Humulin Regular is centrally applied for the chronic management of diabetes mellitus in both adult and pediatric patients to improve overall glycemic control. The primary conditions it is relevant for include Type 1 diabetes, Type 2 diabetes, and Gestational diabetes. This supports a positive trajectory for long-term health, which is critical for minimizing the risk of complications associated with persistent high blood sugar.


It is commonly used when short-term symptomatic assistance is needed for time-sensitive clinical scenarios, such as managing postprandial glucose spikes or providing acute correction of unexpectedly high blood glucose (hyperglycemia). It is applied in addressing symptoms related to systemic imbalance, which may include excessive thirst, frequent urination, and systemic fatigue. Furthermore, it is considered relevant in clinical settings that involve acute or unstable symptom patterns, and may be part of supportive management for conditions such as diabetic ketoacidosis (DKA). This supports general well-being during symptomatic phases.

“The use of this insulin is relevant for easing the overall symptom load and supports the patient during phases of increased metabolic distress.”


Quick Fact: Supportive Management of Hyperglycemia Symptoms Humulin Regular assists with managing groups of symptoms that may become intense, particularly those linked to organ-specific functional stress from severe blood sugar elevation.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

Humulin Regular (Insulin Human) is officially indicated for use in adult and pediatric patients with diabetes mellitus. Eligibility for the medicine is strictly defined by regulatory documents based on absolute prohibitions and conditional use requirements.

Populations Who Must Not Use Humulin Regular (Contraindications)

Classification Condition or Status
Absolute Contraindication Patients currently experiencing hypoglycemia (low blood sugar).
Absolute Contraindication Patients with known hypersensitivity to Humulin Regular or its components.

Populations with Conditional Eligibility

The following groups are eligible, but the official prescribing information states that use requires close monitoring or special caution:

  • Pediatric and Geriatric Patients: Eligible for use, but due to a heightened risk of hypoglycemia, close monitoring is essential.
  • Renal or Hepatic Impairment: Patients with kidney or liver problems are eligible, but the risk of hypoglycemia is higher, requiring increased frequency of blood glucose monitoring.
  • Pregnancy and Lactation: Use is addressed in the label, confirming eligibility while noting the need for close management of glucose control during pregnancy and potential adjustments during lactation.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Humulin Regular almost entirely through pharmacodynamic effects on glucose control. No specific interactions involving CYP enzymes, drug transporters, or mandatory dose-timing separations are listed in the prescribing information.

The documented medicinal product interactions are grouped into two principal categories based on their direct effect on the action of insulin:

  1. Potentiation of Glucose Lowering: Co-administration with certain agents may enhance the blood-glucose-lowering effect, which formally increases the potential for hypoglycemia. This group includes Oral Antidiabetic Drugs, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), salicylates, Monoamine Oxidase Inhibitors (MAOIs), and certain antidepressants like fluoxetine.
  2. Attenuation of Glucose Lowering: Other co-administered agents may reduce the therapeutic blood-glucose-lowering effect. This interaction may result in hyperglycemia. Examples of attenuating substances include Corticosteroids, Diuretics (thiazides), Thyroid Hormones, Oral Contraceptives, and certain Sympathomimetic agents.

The co-administration of alcohol is also explicitly documented as a substance that can potentiate and prolong the glucose-lowering effect. Furthermore, drugs like beta-blockers, clonidine, and reserpine are noted because they can mask the typical physical warning signs of hypoglycemia, altering its clinical manifestation.

Mechanism of Action

Humulin Regular, a human insulin, initiates its action by functioning as an agonist at the insulin receptor (IR), a cell surface transmembrane protein found ubiquitously on target cells, particularly those in skeletal muscle and adipose tissue. Binding to the IR triggers autophosphorylation of the receptor and activates an intracellular signaling cascade. The primary consequence of this cascade is the stimulation of glucose transporter 4 (GLUT4) translocation from intracellular vesicles to the plasma membrane. The presence of these active transporters mediates the enhanced cellular uptake of circulating glucose from the bloodstream, thereby promoting its clearance. Furthermore, the molecular activity of insulin modulates key metabolic pathways by inhibiting hepatic glucose production (gluconeogenesis and glycogenolysis) and lipolysis in adipose tissue. This collective, multifaceted activity influences systemic glucose and lipid metabolism, contributing to the homeostatic regulation of blood glucose concentration at the physiological level.

Dosage and Administration Information

Official Administration Guidelines for Humulin Regular

Administration Scope Details
Route of Administration Subcutaneous injection into the thigh, upper arm, abdomen, or buttocks. Intravenous administration is permitted for the U-100 strength only under proper medical supervision in a clinical setting. The U-500 strength must not be administered intravenously.
Dosing Schedule Dosage must be individualized by a healthcare provider based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. Subcutaneous Humulin R (U-100) is generally used in a regimen with an intermediate- or long-acting insulin. Humulin R U-500 is typically administered two or three times daily.
Timing in Relation to Meals Administer the subcutaneous injection approximately 30 minutes before a meal.
Preparation Requirements Always inspect the solution before use; it must appear clear and colorless and be free of particulate matter. Humulin R U-100 may be mixed with Humulin N only; if mixing, draw Humulin R into the syringe first and inject immediately after mixing. Humulin R U-500 must not be mixed with any other insulins or liquid medicine.
Special Procedural Conditions Rotate injection sites within the same region (abdomen, thigh, upper arm, or buttocks) from one injection to the next to reduce the risk of lipodystrophy. Patients using the Humulin R U-500 vial must use a U-500 insulin syringe to ensure accurate dosing and prevent medication errors. Intravenous infusion must be at a concentration between 0.1 unit/mL to 1 unit/mL in infusion systems containing 0.9% Sodium Chloride Injection.

Recent Clinical Evidence

Research evidence / Overview of studies for Humulin Regular


Evidence for Use in Managing Type 1 Diabetes

Humulin Regular was studied for its use in blood sugar regulation in individuals with Type 1 diabetes, primarily through Randomized Controlled Trials (RCTs) and specialized Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Researchers examined key clinical measures such as changes in Glycated Hemoglobin (HbA1c) and immediate measures like Postprandial Glucose (PPG). Studies also explored the profile of the insulin by monitoring plasma insulin levels and the rate of glucose utilization.

Foundational research provided a baseline for understanding the patterns observed in blood sugar measurements. The specialized PK/PD research describes patterns showing the profile of the drug’s action in the body. However, what remains unclear is the long-term characterization of outcomes compared to newer insulin types. Data for certain groups, particularly concerning factors that affect the body's uptake, are still emerging.


Evidence for Use in Managing Type 2 Diabetes

Research for Type 2 diabetes includes RCTs, Systematic Reviews, and large Observational Studies, especially for its concentrated U-500R formulation. Research examined overall change in the biomarker Glycated Hemoglobin (HbA1c) and monitored outcomes related to physiological strain or stress and patient-reported outcomes describing perceived discomfort. These studies monitored patients with Type 2 diabetes, including older adults and those whose condition was studied for its use in scenarios requiring high daily doses of insulin.

Comparative research explored how its observed patterns related to those of newer rapid-acting insulins. Key research gaps include limited information for long-term outcomes and durability of blood sugar control. Additionally, research focusing on the concentrated U-500R formulation is often derived from observational settings, where evidence quality varies across studies when compared to evidence derived from Randomized Controlled Trials.


Evidence in Specific Patient Populations

Research examined Humulin Regular in several key groups to explore outcomes reflecting daily functioning or activity level.

  • Pediatric Patients: Studies included children and youth with Type 1 diabetes. These trials monitored changes in HbA1c and other blood sugar measures.
  • Pregnant Individuals (Gestational Diabetes): Studies was studied for its use in scenarios involving pregnant women. The research explored short-term changes in maternal blood sugar control, with studies monitoring outcomes related to systemic or functional imbalance. Findings were mixed across systematic reviews, and evidence quality varies across studies.

Key Studies & References

  1. Humulin R (insulin human) injection - Official Drug Label Information
  2. Concentrated Human Insulin U-500 in the Management of Patients with Type 2 Diabetes Mellitus (Review)

Frequently Asked Questions (FAQ)

Common questions about Humulin Regular (FAQ)


Q: Is Humulin Regular the same as Humalog?

A: Humulin Regular and Humalog are two different types of insulin. Humulin Regular is classified in official documents as a short-acting human insulin. Humalog, however, contains the active ingredient insulin lispro, which is classified as a rapid-acting insulin analogue. This means the medicines have different profiles regarding how quickly they start working and how long their effects last.


Q: How quickly should I expect Humulin Regular to start working?

A: According to pharmacokinetic information, the onset of action—the time it takes for the blood sugar-lowering effect to begin—is typically described as starting approximately 30 to 60 minutes after the subcutaneous use of the U-100 strength. The precise onset time can vary depending on individual physiological factors.


Q: How long does the effect of Humulin Regular typically last?

A: Official data indicates that the effect of the U-100 strength, when administered subcutaneously, generally has a duration of action that lasts for 6 to 8 hours. The specific duration can be influenced by several factors noted in regulatory documents, including metabolism and the dose.


Q: What is the typical timeframe for when Humulin Regular reaches its peak activity?

A: The maximum effect, or peak action, of the U-100 strength of Humulin Regular typically occurs approximately 2 to 4 hours after the subcutaneous use. This peak time represents the period where the insulin’s blood glucose-lowering activity is highest.


Q: Does Humulin Regular cause weight gain?

A: Weight gain is listed as a possible adverse reaction observed with insulin therapy in official prescribing information. Concerns regarding changes in weight are typically addressed in the product's full adverse reactions section.


Q: What if I experience mild redness where I use Humulin Regular?

A: Local injection site reactions, such as mild redness, swelling, or itching, are noted as common adverse reactions in official regulatory documents. These minor reactions are generally expected to resolve on their own in a few days to weeks. Persistent or worsening reactions are noted as factors that may warrant medical consultation.


Q: What common medicines or supplements are known to interact with Humulin Regular?

A: Regulatory documents list classes of medicines that may affect how Humulin Regular works. Some medicines, such as certain heart and blood pressure drugs, may increase the blood sugar-lowering effect. Other medicines, such as certain hormone treatments and diuretics, may decrease the blood sugar-lowering effect. Reference to the product's official interaction section is important for a complete overview.


Q: Can taking aspirin affect how Humulin Regular works?

A: Yes, official drug interaction information describes that medicines belonging to the salicylate class, which includes the active ingredient in aspirin, may potentiate (increase) the blood sugar-lowering effect of insulin. This effect is noted in regulatory documents as potentially leading to an enhanced blood glucose-lowering effect.


Q: What happens if Humulin Regular is used with medicines for high blood pressure?

A: Certain common classes of medicines used for high blood pressure, such as ACE inhibitors and ARBs, are listed in regulatory documents as agents that may increase the blood sugar-lowering effect of insulin. The specifics of this interaction are dependent upon the class of medicine co-administered.


Q: What is the safety profile of Humulin Regular during pregnancy?

A: Official information confirms that close management of blood glucose control is important throughout pregnancy. Insulin requirements typically change during pregnancy—often decreasing in the first trimester and increasing in the later stages. This scenario is noted in the labeling as necessitating close monitoring and management.


Q: Why might a doctor prescribe Humulin Regular instead of a long-acting insulin?

A: Regulatory classification defines Humulin Regular as a short-acting insulin with a rapid onset and short duration of effect. This profile makes it suitable for use when quick, temporary blood sugar control is needed, such as managing the temporary rise in blood sugar that may occur after a meal.


Q: Is it true that the effects of Humulin Regular can vary a lot between people?

A: Official prescribing information notes that the dosage for Humulin Regular must be individualized and adjusted based on a patient's specific metabolic needs and response. This requirement for personalization indicates that the individual's response to the medicine can vary significantly.


Q: Is it true that the time it takes for Humulin Regular to start working depends on the site of use?

A: The official prescribing information instructs users to rotate injection sites within the same region (like the abdomen or thigh) to help reduce the risk of tissue changes (lipodystrophy). These tissue changes are noted in regulatory documents as factors that can affect the rate of absorption of insulin and therefore its action.


Q: Does a change in exercise routine require an adjustment consideration for Humulin Regular?

A: Yes, official regulatory documents state that dosage adjustments may be required with changes in physical activity or exercise routines to help maintain blood glucose control.


Q: Is there a patient resource from the FDA or NIH about Humulin Regular?

A: Yes. Authoritative health agencies, including the FDA (via DailyMed) and the NIH (via MedlinePlus), provide official drug information sheets and labeling for the active substance, insulin regular (human), which contains detailed factual information for patients and consumers.


Q: Does Humulin Regular contain pork or beef products?

A: Humulin Regular is a biologic drug whose active ingredient, Insulin Human, is produced using modern recombinant DNA technology. The active ingredient is chemically identical to the insulin naturally produced in the human body.


Q: Is fatigue a common experience when using Humulin Regular?

A: While fatigue is not explicitly listed as a common adverse reaction by itself, official safety information notes that symptoms of the very common adverse reaction, hypoglycemia (low blood sugar), can include feelings of weakness or fatigue.


Q: What does the term 'onset of action' mean for Humulin Regular?

A: Onset of action is a term used in regulatory and pharmacological documents to describe the time required for the insulin's blood glucose-lowering effect to begin after the medicine has been administered.


Q: Are there different forms or strengths of Humulin Regular available?

A: Humulin Regular is available in two main concentrations. These are the standard U-100 (100 units per milliliter) and the more concentrated U-500 (500 units per milliliter). The intended use and administration method vary between the two strengths.


Q: What are the non-directive requirements for storing Humulin Regular?

A: Official storage instructions state that unopened vials must be kept refrigerated and must not be frozen or exposed to heat or direct light. Once opened, vials can be stored either under refrigeration or at room temperature (below 86 F or 30 C) for a maximum of 31 days.


Q: Can other hormone treatments affect the action of Humulin Regular?

A: Yes, official drug interaction information notes that other hormones can affect blood sugar levels. Specifically, thyroid hormones and oral contraceptives are listed as agents that may decrease the blood sugar-lowering effect of insulin.


Q: Is a specific diet required while using Humulin Regular?

A: Regulatory documents emphasize that dosage adjustments may be needed if there are changes in meal patterns or the timing of food intake to help maintain overall glucose control. This highlights the importance of diet management alongside the use of the medicine.


Q: Why do health providers sometimes refer to Humulin Regular as 'R' insulin?

A: The 'R' designation in the name, such as Humulin R, is a shortened way of referring to its regulatory classification as Regular insulin. This term is used to distinguish it from other types of insulin, such as NPH or long-acting versions.


Q: Is it normal to feel a stinging sensation after using Humulin Regular?

A: The adverse reactions profile lists local injection site reactions, which are common. These reactions can include temporary symptoms such as pain, burning, or a stinging sensation at the injection site.


Q: What is the difference between Humulin Regular U-100 and U-500?

A: The difference between the two strengths is the concentration of the medicine. The standard U-100 contains 100 units of insulin per milliliter, while the concentrated U-500 contains five times that amount (500 units per milliliter). The use of these two concentrations is associated with different administration procedures.


Q: Can emotional stress affect how Humulin Regular works?

A: Official regulatory documents acknowledge that physiological changes can influence blood sugar levels. Specifically, periods of emotional stress or acute illness may affect blood glucose levels and are noted as factors that may require dosage consideration.

How should Humulin Regular be stored and disposed of?

Storage and Disposal of Humulin R (Insulin Human) U-100

Official regulatory documents define strict conditions for storing Humulin R to maintain potency and safety.

Storage Requirements

Unopened vials must be stored in a refrigerator between 36 F and 46 F (2 C and 8 C) until the expiration date. The product must not be frozen and must be protected from heat and light. The insulin solution must be clear and colorless; if discoloration or particles are present, the product must be discarded.

In-Use Stability and Safety

Once opened, a vial may be kept for a maximum of 31 days, whether stored under refrigeration or at room temperature (below 86 F or 30 C). The medication must be stored out of the reach of children.

Disposal Instructions

Used syringes and needles must be placed immediately in a dedicated, puncture-resistant sharps disposal container. The disposal of the sealed sharps container and any unused or expired medicine must follow local community guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Humulin Regular  found in:

A-Z Index: